The Third Joint Meeting on Lung Cancer of the FHU OncoAge (University Côte d'Azur, Nice, France) and the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Understanding New Therapeutic Options and Promising Predictive Biomarkers for Lung Cancer Patients

Paul Hofman; George A Calin; Sandurai A Mani; Christophe Bontoux; Marius Ilié; Ignacio I Wistuba

doi:10.3390/cancers14174327

The Third Joint Meeting on Lung Cancer of the FHU OncoAge (University Côte d'Azur, Nice, France) and the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Understanding New Therapeutic Options and Promising Predictive Biomarkers for Lung Cancer Patients

Cancers (Basel). 2022 Sep 4;14(17):4327. doi: 10.3390/cancers14174327.

Authors

Paul Hofman^{1

2

3

4}, George A Calin⁵, Sandurai A Mani⁵, Christophe Bontoux^{1

2

3

4}, Marius Ilié^{1

2

3

4}, Ignacio I Wistuba⁵

Affiliations

¹ Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Université Côte d'Azur, 06000 Nice, France.
² Biobank-Related Hospital (BB-0033-00025), Pasteur Hospital, 06000 Nice, France.
³ FHU OncoAge, Pasteur Hospital, Université Côte d'Azur, 06000 Nice, France.
⁴ Inserm U1081, CNRS UMR 7413, IRCAN, 06100 Nice, France.
⁵ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

We are proud and happy to present this Special Issue, a follow-up to the third joint meeting on lung cancer of the FHU OncoAge (University Côte d'Azur, Nice, France) and the University of Texas MD Anderson Cancer Center (Houston, TX, USA), which was held virtually on 4 October 2021 [...].

Publication types

Editorial

Grants and funding

This research received no external funding.